Generics in India

Generics in India industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2011-15, and forecast to 2020). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the India generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.

The Indian generics market is expected to generate total revenues of $13.1bn in 2015, representing a compound annual growth rate (CAGR) of 14% between 2011 and 2015.

Market consumption volume is forecast to reach a total of 95.1 % of total pharma volume in 2015.

The Indian generics market is one of the largest in the world and the market is set to grow due to an ageing population, increased consumer spending, raising healthcare insurance, and rapid urbanization.

Scope

Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in India

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in India

Leading company profiles reveal details of key generics market players’ global operations and financial performance

Add weight to presentations and pitches by understanding the future growth prospects of the India generics market with five year forecasts by both value and volume

Macroeconomic indicators provide insight into general trends within the India economy

Reasons to buy

What was the size of the India generics market by value in 2015?

What will be the size of the India generics market in 2020?

What factors are affecting the strength of competition in the India generics market?

How has the market performed over the last five years?

How large is India’s generics market in relation to its regional counterparts?

Companies mentioned

Aurobindo Pharma Limited, Cipla Limited, Lupin Limited, Sun Pharmaceutical Industries Ltd.

Table of Contents

TABLE OF CONTENTS

Executive Summary 2

Market value 2

Market value forecast 2

Market volume 2

Market volume forecast 2

Geography segmentation 2

Market rivalry 2

Market Overview 7

Market definition 7

Market analysis 7

Market Data 8

Market value 8

Market volume 9

Market Segmentation 10

Geography segmentation 10

Market Outlook 11

Market value forecast 11

Market volume forecast 12

Five Forces Analysis 13

Summary 13

Buyer power 14

Supplier power 15

New entrants 16

Threat of substitutes 17

Degree of rivalry 18

Leading Companies 19

Aurobindo Pharma Limited 19

Cipla Limited 22

Lupin Limited 25

Sun Pharmaceutical Industries Ltd. 29

Macroeconomic Indicators 32

Country Data 32

Methodology 34

Industry associations 35

Related MarketLine research 35

Appendix 36

About MarketLine 36

List of Tables

Table 1: India generics market value: $ billion, 201115(e)

Table 2: India generics market volume: % of total pharma volume, 201115(e)

Table 3: India generics market geography segmentation: $ billion, 2015(e)

Table 4: India generics market value forecast: $ billion, 201520

Table 5: India generics market volume forecast: % of total pharma volume, 201520

Table 6: Aurobindo Pharma Limited: key facts

Table 7: Aurobindo Pharma Limited: key financials ($)

Table 8: Aurobindo Pharma Limited: key financials (Rs.)

Table 9: Aurobindo Pharma Limited: key financial ratios

Table 10: Cipla Limited: key facts

Table 11: Cipla Limited: key financials ($)

Table 12: Cipla Limited: key financials (Rs.)

Table 13: Cipla Limited: key financial ratios

Table 14: Lupin Limited: key facts

Table 15: Lupin Limited: key financials ($)

Table 16: Lupin Limited: key financials (Rs.)

Table 17: Lupin Limited: key financial ratios

Table 18: Sun Pharmaceutical Industries Ltd.: key facts

Table 19: Sun Pharmaceutical Industries Ltd.: key financials ($)

Table 20: Sun Pharmaceutical Industries Ltd.: key financials (Rs.)

Table 21: Sun Pharmaceutical Industries Ltd.: key financial ratios

Table 22: India size of population (million), 201115

Table 23: India gdp (constant 2005 prices, $ billion), 201115

Table 24: India gdp (current prices, $ billion), 201115

Table 25: India inflation, 201115

Table 26: India consumer price index (absolute), 201115

Table 27: India exchange rate, 201115

List of Figures

Figure 1: India generics market value: $ billion, 201115(e)

Figure 2: India generics market volume: % of total pharma volume, 201115(e)

Figure 3: India generics market geography segmentation: % share, by value, 2015(e)

Figure 4: India generics market value forecast: $ billion, 201520

Figure 5: India generics market volume forecast: % of total pharma volume, 201520

Figure 6: Forces driving competition in the generics market in India, 2015

Figure 7: Drivers of buyer power in the generics market in India, 2015

Figure 8: Drivers of supplier power in the generics market in India, 2015

Figure 9: Factors influencing the likelihood of new entrants in the generics market in India, 2015

Figure 10: Factors influencing the threat of substitutes in the generics market in India, 2015

Figure 11: Drivers of degree of rivalry in the generics market in India, 2015

Figure 12: Aurobindo Pharma Limited: revenues & profitability

Figure 13: Aurobindo Pharma Limited: assets & liabilities

Figure 14: Cipla Limited: revenues & profitability

Figure 15: Cipla Limited: assets & liabilities

Figure 16: Lupin Limited: revenues & profitability

Figure 17: Lupin Limited: assets & liabilities

Figure 18: Sun Pharmaceutical Industries Ltd.: revenues & profitability

Figure 19: Sun Pharmaceutical Industries Ltd.: assets & liabilities

List of Tables

NA

List of Figures

NA

    Pricing

Quick Buy
Add to basket Enquire before buying

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports